- recruiting
Rebooting Infant Pain Assessment: Using Machine Learning to Exponentially Improve Neonatal Intensive Care Unit Practice
This study uses smart computer programs to better understand and manage pain in premature babies in intensive care. By looking at how babies react to minor procedures, researchers hope to develop a tool that helps nurses and doctors tell the difference between pain and other kinds of discomfort.
Canada · United Kingdom - recruitingNA
Performance and Safety of LightForce® Therapy Lasers on Lateral Ankle Sprain
This study looks at how well LightForce laser therapy, combined with standard care (RICE and exercise), helps reduce pain from ankle sprains compared to standard care alone. It also checks the laser's safety.
Italy · United Kingdom - authorisedTherapeutic confirmatory (Phase III)
An open label, pharmacokinetic and safety study of Combogesic® IV in pediatric patients with acute pain.
This study is looking at a new way to give pain relief through an IV drip called Combogesic® IV. We want to see how safe it is and how well the body uses it in children and young people who are in pain.
Hungary - authorisedTherapeutic use (Phase IV)
A randomized, Phase 4, double-blind, placebo-controlled, 6-arm crossover study to investigate the systemic effect of lidocaine and ropivacaine when used for Transversus Abdominis Plane (TAP) blocks on hyperalgesia and pain perception in healthy volunteers aged 18 to 64 years.
This study looks at how well two common pain-numbing medicines, lidocaine and ropivacaine, work to reduce pain sensitivity. Healthy men aged 18 and over will take part. We want to understand their effects when used in a specific type of pain block.
Norway - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Single Dose Crossover Comparative Bioavailability and Food Effect Study of Celecoxib 10 mg/1 mL Oral Suspension versus Celebrex®️ (celecoxib) 200 mg Capsules Following the Administration of a 200 mg Dose in Healthy Adult Volunteers / Fasting and Fed State.
Czechia